Prostacyclin administration as a beneficial supplement to the conventional cancer chemotherapy

Jiansheng Wang, Jia Zhang, Junping Sun, Jiangli Han, Yutao Xi, Geru Wu, Kristina X. Duan, Mingxin Zhang, Suna Zhou, Qi Liu

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Prostacyclin (PGI2) and its analogues protect from cardiovascular disease through pleiotropic effects such as vasodilation, inhibition of platelet aggregation, leukocyte adhesion, and vascular smooth muscle cell (VSMC) proliferation. Additionally, prostacyclin synthase (PGIS) and PGI2 also possess anti-cancer properties. As of late (2009-2010), numerous studies have identified the deleterious side-effects of chemotherapy on the cardiovascular system, which have been deemed as a serious clinical issue. Cardiomyocyte damage, induced by oxidative stress, is one of the clinical consequences caused by routine cancer chemotherapy. Previous studies indicate iloprost, a PGI2 analogue, can protect against doxorubicin-induced (DOX) cardiomyocyte injury in vitro and in vivo without compromising tumor suppression. Therefore, we hypothesize PGI2 can be used as a cardioprotective supplement to attenuate the damaging cardiac effects caused by the traditional cancer chemotherapy regimen.

Original languageEnglish (US)
Pages (from-to)695-696
Number of pages2
JournalMedical Hypotheses
Issue number5
StatePublished - May 2011
Externally publishedYes

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Prostacyclin administration as a beneficial supplement to the conventional cancer chemotherapy'. Together they form a unique fingerprint.

Cite this